Form 4: Monopar Director Starr Granted Stock Options

Monopar Therapeutics director Christopher M. Starr was granted 2,924 stock options with an exercise price of $75.94, vesting quarterly through 2026.

Summary

• Christopher M. Starr, a Director of Monopar Therapeutics (MNPR), was granted 2,924 stock options.
• The transaction date for this grant was December 2, 2025.
• Each option has an exercise price of $75.94.
• The options will vest quarterly in four equal installments of 25% on March 31, 2026, June 30, 2026, September 30, 2026, and December 31, 2026.
• The options have an expiration date of December 2, 2035.
• Following this transaction, Christopher M. Starr beneficially owns 2,924 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The filing reports a routine insider transaction (stock option grant) which is generally viewed as a neutral to slightly positive event, indicating continued alignment of a director's interests with the company's long-term performance. It does not contain information that would significantly alter the company's financial outlook or operations.

Positives

• The grant of stock options to a director aligns management's interests with those of shareholders, incentivizing long-term company performance.

Future Outlook

The future outlook for the granted options is tied to the company's stock performance relative to the $75.94 exercise price and the successful vesting of the options over the specified quarterly schedule through 2026.

Industry Context

The grant of stock options is a common form of executive and director compensation in the biotechnology and pharmaceutical industry, aiming to retain talent and align leadership incentives with long-term shareholder value creation. Such grants are standard practice for publicly traded companies like Monopar Therapeutics.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors in the biotech sector, comparable to practices at peer companies like Xencor (XNCR) or Blueprint Medicines (BPMC) which also utilize equity incentives to attract and retain leadership.
• The vesting schedule, typically over several years, is consistent with industry norms designed to encourage long-term commitment and performance.

Related Party Transactions

• Christopher M. Starr, a Director of Monopar Therapeutics, received a grant of 2,924 stock options from the company, which constitutes a transaction between the company and a related party (an insider).

Stakeholder Impact

• Shareholders: The grant of options aims to align the director's financial interests with long-term shareholder value, potentially leading to more focused strategic decisions.
• Employees: While not directly impacting general employees, such compensation practices for leadership can influence overall company culture and perception of executive incentives.

Next Steps

• The granted stock options will vest quarterly, with the first tranche on March 31, 2026, and subsequent tranches on June 30, 2026, September 30, 2026, and December 31, 2026.

Key Dates

Keywords

Monopar Therapeutics, MNPR, stock options, director compensation, insider transaction, Form 4, equity grant